AtaiBeckley reports rapid and durable antidepressant response in Phase 2a trial of BPL-003

AtaiBeckley (NASDAQ:ATAI), a clinical-stage biopharmaceutical company developing next-generation mental health treatments, reported on April 8, 2026, peer-reviewed Phase 2a results demonstrating that a single intranasal dose of BPL-003 achieved rapid and sustained clinical benefits in patients with Treatment-Resistant Depression (TRD).

The study evaluated BPL-003—a proprietary intranasal formulation of 5-MeO-DMT—in 12 patients who were concurrently receiving stable doses of selective serotonin reuptake inhibitors (SSRIs).

The data revealed a 66.7% antidepressant response rate as early as Day 2 following a single administration, highlighting the candidate's potential for rapid onset of action.

Crucially, the clinical benefits proved durable over the long term.

At the Day 85 follow-up, the study reported an 83% response rate in the 10 mg cohort and a 66.7% response rate in the 12 mg cohort.

The findings suggest that BPL-003 could offer a significant shift in the treatment paradigm for TRD, a condition where patients have failed to improve after multiple conventional antidepressant trials.

The positive data follows the FDA’s decision to grant BPL-003 Breakthrough Therapy designation in October 2025, a status intended to expedite the development and review of drugs that demonstrate substantial improvement over existing therapies.

Following a successful End-of-Phase 2 alignment with the FDA, AtaiBeckley confirmed that it remains on track to initiate a pivotal Phase 3 program in the second quarter of 2026.

The Phase 3 trial is expected to be the largest study of its kind for an intranasal psychedelic-based compound, focusing on safety and efficacy in a broader TRD population.

Treatment-Resistant Depression affects an estimated 100 million people globally, representing a multi-billion dollar market opportunity with high unmet medical needs.

AtaiBeckley's intranasal delivery system is designed to provide a predictable and non-invasive administration experience in a supervised clinical setting, typically requiring less than two hours of patient monitoring.